Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 4;5(4):573–588. doi: 10.1002/hep4.1657

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Fig. 6 — Effects of resmetirom on RT3 and FT3/RT3 in patients with NASH. (A) Baseline FT3/RT3 in normal (non‐NASH) and NASH according to liver biopsy fibrosis stage. Shown as a box and whisker plot with box defined by quartile 1, 3, and median, with quartile line shown; “x” indicates the mean, SD, and error bars. (B) Effect of resmetirom on thyroid pathway hormones at week 36 in the main study or OLE. Compared with placebo in the main study, within‐group comparison over time in the OLE. Abbreviation: F2/F3, patients with baseline NASH fibrosis stage of F2 or F3.